Key statistics
As of last trade Roche Holding AG (RHO6:DUS) traded at 33.80, -11.29% below its 52-week high of 38.10, set on Sep 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 33.80 |
---|---|
High | 33.80 |
Low | 33.80 |
Bid | 33.90 |
Offer | 35.30 |
Previous close | 33.80 |
Average volume | 115.29 |
---|---|
Shares outstanding | 6.47bn |
Free float | 331.63m |
P/E (TTM) | 19.16 |
Market cap | 233.72bn USD |
EPS (TTM) | 1.85 USD |
Data delayed at least 15 minutes, as of Nov 25 2024 07:12 GMT.
More ▼
- Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024
- Roche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer’s disease
- New England Journal of Medicine publishes landmark phase III results for Roche’s Itovebi, showing more than doubling of progression-free survival in certain type of HR-positive advanced breast cancer
- [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong sales growth of 9% (CER) continues in the third quarter of 2024; Group sales increase 6% in the first nine months
- [Ad hoc-Mitteilung gemäss Art. 53 KR] Starkes Verkaufswachstum der Roche-Gruppe von 9% (CER) auch im dritten Quartal 2024; Konzernverkäufe steigen in den ersten neun Monaten um 6%
- Roche’s Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study
- Majority of children with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi are able to sit, stand and walk independently, two-year data demonstrate
- FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
- Roche obtains CE certification for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY
- Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis
More ▼